| Literature DB >> 32298669 |
Lucia Pažitná1, Marek Nemčovič1, Zuzana Pakanová1, Peter Baráth1, Teimur Aliev2, Dmitry Dolgikh3, Victoria Argentova4, Jaroslav Katrlík5.
Abstract
Glycosylation of therapeutic glycoproteins significantly affects their physico-chemical properties, bioactivity and immunogenicity. The determination of glycan composition is highly important regarding their development and production. Therefore, there is a demand for analytical techniques enabling rapid and reliable glycoprofiling of therapeutic proteins. For the investigation of changes in glycan structures, we have employed two platforms: lectin-based protein microarray, and MALDI-MS. In lectin-based microarray analysis, the samples of IgA were printed on the microarray slide, incubated with the set of lectins with various specificity and evaluation of changes in glycosylation was based on differences in reactivity of samples with lectins. MALDI-MS was used for N-glycan analysis of IgA1 samples. IgAs are effective as therapeutic agents in defense against viruses that use sialic acid as a receptor. Dimeric IgA1 antibodies were produced by stable cell line IgA1/2G9 on the basal medium at different conditions (different supplementation and feeding) and we also evaluated the effect of different conditions on lactate production, which correlates with IgA productivity. Decrease of lactate levels was observed during supplementation with succinic acid, asparagine, or with mannose feeding. We found by lectin-based microarray analysis that the metabolic shift from glutamine to asparagine or feeding with glucose caused increase of high mannose type glycans what was confirmed also by MALDI-MS. Among other changes in IgA glycosylation determined by lectin-based protein microarray were, for example, reduced galactosylation after supplementation with succinic acid and increase of both sialylation and galactosylation after supplementation with glutamine and feeding with mannose. The elucidation of mechanism of determined changes requires further investigation, but the described analytical approach represent effective platform for determination, screening and evaluation of glycosylation of therapeutic proteins.Entities:
Keywords: Glycosylation; IgA; Lectin-based microarray; MALDI-MS; Monoclonal antibody; Therapeutic proteins
Mesh:
Substances:
Year: 2020 PMID: 32298669 PMCID: PMC7194684 DOI: 10.1016/j.jbiotec.2020.03.009
Source DB: PubMed Journal: J Biotechnol ISSN: 0168-1656 Impact factor: 3.307
Lectins used in lectin-based microarray analysis and their key sugar specificity.
| Lectin | Key sugar specificity | |
|---|---|---|
| SNA | Siaα2−6 Gal/GalNAc | |
| ConA | Manα1−6Man, Manα1−3Man, Manα1−2Man, high mannose | |
| MAL-I | Siaα2−3Galβ1−4GlcNAc | |
| MAL-II | Siaα2−3Galβ1−3(±Siaα2−6)GalNAc | |
| PHA-E | di-/triantennary complex type N-glycans with bisecting GlcNAc | |
| PHA-L | tri-/tetraantennary complex type N-glycans with GlcNAcβ1−6Man | |
| WGA | GlcNAcβ1−4GlcNAc, Sia | |
| RCA | Galβ1−4GlcNAc, GalNAc, Gal | |
| AAL | Fucα1−6GlcNAc, Fucα1−3(Galβ1−4)GlcNAc | |
| PhoSL | Fucα1−6GlcNAc | |
| GNL | Manα1−3Man, high mannose type N-glycans | |
| GSL-I | Gal, GalNAc | |
| PNA | Galβ1−3GalNAc | |
| HHL | Manα1−3Man, Manα1−6Man, high mannose type N-glycans | |
| NPL | Manα1−6Man, high mannose type N-glycans | |
| LCA | αMan in N-glycans with core fucose, αMan in N-glycans | |
| Symbolic representation of monosaccharides | ||
Fig. 1Effect of glutamine, succinic acid and asparagine on the cell concentration (A), IgA1 production (B) and lactate level (C). Cell culture was grown on IMDM medium with different supplements: 1 – IMDM +8 mM glutamine (control); 2 – IMDM +8 mM asparagine; 3 - IMDM +8 mM succinic acid.
Fig. 2Effects of different carbon sources on the cell concentration (A), IgA1 production (B) and lactate level (C). Cell culture was grown on IMDM medium with different feeding supplements.
Fig. 3Normalized signals of interactions of IgA1/2G9 samples with lectins measured by lectin-based protein microarray.
Fig. 4Reflectron positive MALDI TOF spectra (m/z 1500 - 2900) of released N-glycans, with representative N-glycan structures found in the samples. Data of intensity values are in the Table S1 in the Supplementary File.